Business Context and Reporting Period
This Form 8-K was filed by Pavmed Inc. on August 10, 2021. The report discloses a material event under Item 7.01 (Regulation FD Disclosure) regarding the operational activities of its majority-owned subsidiary, Lucid Diagnostics Inc. ("Lucid").
Key Financial Metrics
The filing text does not provide specific financial data, including revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on a non-financial operational update.
Material Changes
The primary material change reported is the commencement of patient testing by Lucid Diagnostics. Specifically:
- Lucid has begun testing patients referred by primary care physicians.
- Testing is occurring at three Lucid Test Centers located in the Phoenix metropolitan area.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of risks and contingencies. The disclosure is limited to the announcement of the operational milestone. The press release associated with this item is included as Exhibit 99.1 but is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the operational status and capacity of the three Lucid Test Centers in Phoenix.
- Confirm the volume of patient referrals received from primary care physicians to date.
- Review the full text of the press release (Exhibit 99.1) for additional operational details not summarized in the 8-K.
- Monitor future filings for financial impact resulting from the expansion of testing services.